Syros Pharmaceuticals (SYRS) & Peregrine Pharmaceuticals (PPHM) Head-To-Head Survey

Syros Pharmaceuticals (NASDAQ: SYRS) and Peregrine Pharmaceuticals (NASDAQ:PPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Syros Pharmaceuticals and Peregrine Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals 0 2 6 0 2.75
Peregrine Pharmaceuticals 0 0 1 0 3.00

Syros Pharmaceuticals currently has a consensus target price of $23.83, indicating a potential upside of 137.39%. Peregrine Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 151.89%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Peregrine Pharmaceuticals is more favorable than Syros Pharmaceuticals.

Volatility and Risk

Syros Pharmaceuticals has a beta of -3.72, indicating that its share price is 472% less volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500.

Institutional & Insider Ownership

58.0% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 18.7% of Peregrine Pharmaceuticals shares are held by institutional investors. 33.6% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Peregrine Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Syros Pharmaceuticals and Peregrine Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syros Pharmaceuticals $320,000.00 825.16 -$47.74 million ($2.01) -5.00
Peregrine Pharmaceuticals $57.63 million 3.11 -$28.15 million ($0.81) -4.90

Peregrine Pharmaceuticals has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Peregrine Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Syros Pharmaceuticals and Peregrine Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syros Pharmaceuticals N/A -62.01% -55.65%
Peregrine Pharmaceuticals -39.23% -52.55% -24.77%

Summary

Peregrine Pharmaceuticals beats Syros Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Peregrine Pharmaceuticals Company Profile

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit